-
Pharmacogenomics allows for the individualization of drug treatment by assessing the potential that a drug agent will be efficacious due to ______ considerations and prevent toxicities due to _____ considerations
-
Biotransformation via the_______ represents one of the most common elimination mechanisms
cytochrome P450s
-
15-30% of the most commonly used drugs are metabolized by the _______ isoform alone
CYP2D6
-
Tamoxifen is metabolized by 9 CYP isoforms, as well as the ______________
flavin monooxygenase
-
_____________ reduces excess superoxide anion
Superoxide dismutase
-
Oxygen binds to CYP via a __________________________
non-covalent iron-protoporphyrin IX ring (heme)
-
________________ compares evolution of different families across species
phylogenic tree
-
What organ contains the most diverse array of CYP450 proteins
liver
-
The CYP4B1 isoform is located in which tissue
lungs
-
In what tissue is the CYP4F8 isoform located
prostate
-
CYP11A, 11B1, 11B2 isoforms are found in the
adrenal glands
-
The CYP24 isoform is located where
kidneys
-
Which CYP isoform preferentially binds polar heterocyclic compounds and aryl amines
CYP1A2
-
The majority of the CYPs expressed on the intestines & liver belong to which sub-family
3A
-
Gene sequence changes shown in CYP450 genes that impact enzymatic activity
Phenotypic Variation
-
The phenotype that has no function alleles present
poor metabolizer
-
The phenotype that has either one funtionsl and one mutant/deficient allele or two partially active/deficient alleles present
intermediate metabolizer
-
The phenotype that has either 2 active alleles or a combination of one active and one partially active allele present
extensive metabolizer
-
The phenotype that has 3 or more active alleles present
ultrarapid metabolizer
-
Which phenotypic metabolizer should be able to achieve therapeutic effects at normal dosing?
(I know this is poorly worded)
extensive metabolizer
-
What non-CYP450 super family of phase I enzymes are expressed in the liver, intestines, and ER membranes
flavin monooxygenase
-
What is an alternative to genotyping CYP450 alleles
phenotyping
-
The assays for phenotyping are based on the ________ of substrate drugs that have been labeled with a stable or radioactive carbon
demethylation
-
What substrate is used for a CYP3A4 breath test
erythromycin
-
What substrate is used for a CYP1A2 breath test
caffeine
-
What substrate is used for a CYP2C19 breath test
aminopyrine
-
erythromycin will undergo ____________ by CYP3A4
demethylation
-
CYP1A2 is aslo known as
Aryl hydrocarbon hydroxylase
-
CYP2D6 aka
debrisoquine/sparteine hydroxylase
-
CYP2C19 aka
S-mephenytoin hydroxylase
-
Smoking has what effect on CYP1A2
induction
-
theophylline, clozapine, & olanzapine are metabolized by which CYP
CYP1A2
-
clopidogrel, proton pump inhibitors, and phenytoin are metabolized by which CYP
CYP2C19
-
phenytoin, warfarin, and sulfonylureas are metabolized by which CYP
CYP2C9
-
bupropion, cyclophosphamide, methadone, & nevirapine are metabolized by which CYP
CYP2B6
-
What is the most frequent allele of the CYP2B6 isoform
CYP2B6*6
-
Mutant alleles generally have _________ catalytic activity of the expressed protein
reduce
-
Preferential substrates of CYP2C9 are _______ compounds having 1 or more ____________
- weakly acidic
- aromatic rings
-
Patients with the poor metabolizer alleles will show a 5X greater instance of _________ upon starting an oral sulfonylurea antihyperglycemic agent.
hypoglycemia
-
Ultra-rapid metabolizers will have _____________ levels of the oral sulfonylurea antihyperglycemic agents
decreeased
-
The FDA recommends _____ & _____ genotyping for warfarin
-
CYP2C19 is also know as
S-mephenytoin hydroxylase
-
Beta blockers are deactivated by CYP2D6 therefore which phenotype would result in a higher risk for therapeutic failure
ultra-rapid metabolizer
-
Poor metaboliazer alleles for CYP2C19 are
*2 & *3
|
|